B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more. B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more. | | |
|
New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension. New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension. | | |
|
The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns. The FDA has detailed three voluntary recalls for prazosin hydrochloride, a medication used to treat hypertension, due to safety concerns. | | |
|
The company, founded in 1966, has been providing supplies to cardiac surgery suites and cath labs for decades. The company, founded in 1966, has been providing supplies to cardiac surgery suites and cath labs for decades. | | |
|
|
Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco. Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco. | | |
|
The patient's Trifecta GT heart valve had to be replaced after just six years, an experience he says resulted in "permanent injuries." Abbott pulled the devices off the U.S. market in 2023 due to a known risk of structural valve deterioration. The patient's Trifecta GT heart valve had to be replaced after just six years, an experience he says resulted in "permanent injuries." Abbott pulled the devices off the U.S. market in 2023 due to a known risk of structural valve deterioration. | | |
|
Circle Cardiovascular Imaging, a Canadian medtech company, received the key approval for its cvi42 | Plaque platform. Circle Cardiovascular Imaging, a Canadian medtech company, received the key approval for its cvi42 | Plaque platform. | | |
|
Shockwave Medical and FastWave Medical have shared new first-in-human data on their advanced IVL offerings. Both companies are focused on addressing difficult-to-cross lesions that often cause problems for cardiologists. Shockwave Medical and FastWave Medical have shared new first-in-human data on their advanced IVL offerings. Both companies are focused on addressing difficult-to-cross lesions that often cause problems for cardiologists. | | |
|
|
More research is still required, but Field Medical's FieldForce Ablation System may represent a significant step forward in the treatment of scar-related ventricular tachycardia. More research is still required, but Field Medical's FieldForce Ablation System may represent a significant step forward in the treatment of scar-related ventricular tachycardia. | | |
|
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away. Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away. | | |
|
Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults. Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults. | | |
|
|
The U.S. Department of Justice says Nicole Millen—who is neither a medical doctor nor a veterinarian—gave visitors to her clinics Chorulon, a drug meant for cows, without properly labeling it as for animal use only. The U.S. Department of Justice says Nicole Millen—who is neither a medical doctor nor a veterinarian—gave visitors to her clinics Chorulon, a drug meant for cows, without properly labeling it as for animal use only. | | |
|
The allegations are part of a 13-count indictment unveiled Monday by Massachusetts Attorney General Andrea Joy Campbell listing Blooming Staffing Agency, its owner and an employee as defendants. They are accused of billing nursing homes after knowingly placing unlicensed nursing assistants to care for elderly patients. The allegations are part of a 13-count indictment unveiled Monday by Massachusetts Attorney General Andrea Joy Campbell listing Blooming Staffing Agency, its owner and an employee as defendants. They are accused of billing nursing homes after knowingly placing unlicensed nursing assistants to care for elderly patients. | | |
|
